FLGT — Fulgent Genetics, Inc.

Fulgent Genetics Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $85.4 million, up 4% year-over-year and 20% sequentially, driven by the full integration of Bako Diagnostics and StrataDX.
• Segment Performance:
  • Precision Diagnostics: $41.5 million, down 13% year-over-year but up 3% sequentially.
  • Anatomic Pathology: $37.5 million, up 33% year-over-year and 50% sequentially.
  • BioPharma Services: $6.4 million, up 3% year-over-year and 11% sequentially.
• Gross Margin: GAAP gross margin at 30.1%; non-GAAP gross margin at 31.3%, reflecting a decline due to lower collection rates.
• Operating Expenses: GAAP operating expenses increased to $61.8 million, including a $2.2 million impairment charge.
• Net Loss: GAAP loss of $29.5 million ($1.05 per share); non-GAAP loss of $16.2 million ($0.58 per share).
• Adjusted EBITDA: Loss of approximately $17.1 million, worsening from the previous quarter.
• Cash Position: Ended the quarter with approximately $551.5 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• Therapeutic Development: Progress on clinical pipeline, particularly with FID-007 for head and neck cancer, with plans for a Phase III trial in H1 2027. FID-022 is also advancing to Phase I.
• AI and Digital Pathology: Continued expansion of AI capabilities, including a novel algorithm for mast cell quantification, enhancing diagnostic efficiency.
• Acquisition Integration: Successful integration of Bako and StrataDX, with minimal disruption to operations and a nearly doubled sales team.
• Partnerships: Open to collaborations that align with long-term strategic goals.

3. Forward Guidance and Outlook

• Revised Revenue Guidance: Total revenue expected between $330 million to $340 million for 2026, down from $350 million. This reflects a 2.3% to 5.4% year-over-year growth.
• Segment Revenue Estimates: Precision Diagnostics at $161 million to $166 million; Anatomic Pathology at $146 million to $150 million; BioPharma Services at $23 million to $24 million.
• Margins: Full-year non-GAAP gross margins expected in the mid-30% range, with operating margins in the mid-minus 20% range.
• EPS Guidance: Non-GAAP EPS loss projected between $2.22 to $2.35 per share.

4. Bad News, Challenges, or Points of Concern

• Revenue Cycle Management (RCM) Issues: Transition to a new billing system has led to delays in billing and lower collection rates, impacting revenue recognition.
• Customer Concentration Risk: Revenue from the largest customer decreased significantly as they moved testing in-house, with expectations of continued decline.
• Impairment Charge: A one-time impairment charge of $2.2 million related to lost customer relationships in the therapeutic segment.
• Operational Challenges: The complexity of the new billing system has caused significant operational hurdles, with no clear timeline for full resolution.

5. Notable Q&A Insights

• RCM Transition: Management acknowledged specific features from the old system were not transferred, causing delays. They expect to return to historical collection rates in the coming quarters.
• Impact of Customer Transition: The transition of the large carrier screening customer to in-house operations is nearly complete, with minimal revenue expected from them moving forward.
• Future Revenue Recovery: While there is potential for recovering some delayed collections, management emphasized the need to first stabilize the collection rates before making predictions.

Overall, Fulgent Genetics is navigating challenges related to revenue collection and customer transitions while making strategic investments in its therapeutic pipeline and AI capabilities. The revised guidance reflects these operational hurdles but maintains a focus on long-term growth potential.